Bortezomib in Late Antibody-mediated Kidney Transplant Rejection

NCT01873157 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

44

Enrollment

OTHER

Sponsor class

Conditions

Late Rejection of Renal Transplant
Antibody-mediated Rejection

Interventions

DRUG: Bortezomib
DRUG: Placebo

Sponsor

Medical University of Vienna

Collaborators

[object Object]